Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linrodostat + Nivolumab +/- Ipilimumab in Advanced Tumors
NCT02658890Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2016
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of linrodostat in solid tumor, melanoma, non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Apr 2016; status: completed.
02
Drugs
linrodostat
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02658890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658890.